Novavax
NVAX
$14.40
Share price
-4.32%
Change (1 day)
78.66%
Change (1 year)
Categories
Novavax (NVAX) - P/B ratio
P/B ratio as of June 2024 : -2.56
According to Novavax's latest financial reports the company has a price-to-book ratio of -2.56.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Novavax - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | -0.7953 | -42.29% |
| 2022-12-31 | -1.38 | -95.52% |
| 2021-12-31 | -30.8 | -371.78% |
| 2020-12-31 | 11.3 | -1735.05% |
| 2019-12-31 | -0.6922 | -83.57% |
| 2018-12-31 | -4.21 | -7.94% |
| 2017-12-31 | -4.58 | -92.57% |
| 2016-12-31 | -61.6 | -896.25% |
| 2015-12-31 | 7.74 | 25.48% |
| 2014-12-31 | 6.17 | 17.34% |
| 2013-12-31 | 5.26 | 50.85% |
| 2012-12-31 | 3.48 | 29.53% |
| 2011-12-31 | 2.69 | -41.12% |
| 2010-12-31 | 4.57 | 19.85% |
| 2009-12-31 | 3.81 | 32.66% |
| 2008-12-31 | 2.87 | -12.14% |
| 2007-12-31 | 3.27 | 21.37% |
| 2006-12-31 | 2.70 | -36.5% |
| 2005-12-31 | 4.24 | 9.54% |
| 2004-12-31 | 3.87 | -33.15% |
| 2003-12-31 | 5.80 | -27.94% |
| 2002-12-31 | 8.04 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 5.44 | -312.83% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.69 | -166.21% | 🇺🇸 USA |
 AstraZeneca AZN | 6.58 | -357.19% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 5.01 | -296.12% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 12.3 | -580.80% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 2.86 | -211.99% | 🇺🇸 USA |
 Agenus
AGEN | -1.77 | -30.95% | 🇺🇸 USA |
 NanoViricides NNVC | 2.86 | -211.93% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | -2.70 | 5.61% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.4767 | -118.65% | 🇺🇸 USA |